09-07-2025
Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's blockbuster weight loss drugs Ozempic and Wegovy starting in January 2026. Brandon Gomez unpacks the details.